sonidegib   

GtoPdb Ligand ID: 8199

Synonyms: erismodegib (deleted INN) | LDE-225 | LDE225 | NVP-LDE225 | Odomzo®
sonidegib is an approved drug (EMA & FDA (2015))
Compound class: Synthetic organic
Comment: Sonidegib (INN formerly erismodegib, but replaced in 2012) is an orally active inhibitor of the hedgehog signalling pathway, acting as an antagonist of the class frizzled GPCR, smoothened (SMO) [1-2].
The first hedgehog pathway inhibitor to be approved was vismodegib (2012).
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 63.69
Molecular weight 485.19
XLogP 6.86
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Canonical SMILES CC1OC(C)CN(C1)c1ccc(cn1)NC(=O)c1cccc(c1C)c1ccc(cc1)OC(F)(F)F
Isomeric SMILES C[C@@H]1O[C@H](C)CN(C1)c1ccc(cn1)NC(=O)c1cccc(c1C)c1ccc(cc1)OC(F)(F)F
InChI InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
InChI Key VZZJRYRQSPEMTK-CALCHBBNSA-N
No information available.
Summary of Clinical Use
In 2015, the EMA and FDA approved sonidegib as a treatment for locally advanced basal cell carcinoma (recurring after surgery/radiation therapy or in patients for whom the latter are not an option). Phase II trials for cancers including multiple myeloma, platinum resistant recurrent ovarian cancer and ER/HER2 negative breast cancers, medulloblastoma and pancreatic cancer are ongoing. Click here to link to ClinicalTrials.gov's full listing of sonidegib trials.
External links